Key result
Apixaban and rivaroxaban linked to lower bleeding and intracranial hemorrhage rates versus LMWH in cancer-associated VTE.
Why the study?
Evidence regarding the comparative safety of direct oral anticoagulants versus low-molecular-weight heparin in patients with cancer-associated venous thromboembolism remains very limited.
Do direct oral anticoagulants (apixaban, rivaroxaban) reduce bleeding compared to low-molecular-weight heparin in patients with venous thromboembolism and cancer?
Observational
Yes
Do direct oral anticoagulants (apixaban, rivaroxaban) reduce bleeding compared to low-molecular-weight heparin in patients with venous thromboembolism and cancer?
Real-world evidence supports DOACs (apixaban and rivaroxaban) as safe alternatives to LMWH for patients with cancer-associated VTE, with potentially lower bleeding risks.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating real-world data on DOACs for cancer-VTE should not yet change practice; leaves open validation in randomized trials.
These findings suggest that apixaban may offer a safer bleeding profile than LMWH for patients with cancer-associated VTE, particularly in reducing overall and other types of bleeding. Rivaroxaban also appears to be a viable alternative to LMWH, with a notably lower risk of ICH. These results provide valuable real-world insights in an area where evidence remains very limited and support the role of DOACs as a safe alternative to LMWH in patients with VTE and cancer.
No takes yet. Share an insight, caveat, or question.
Brodin et al. (2026) conducted an observational in Venous thromboembolism and cancer. Direct oral anticoagulants (apixaban, rivaroxaban) vs. Low-molecular-weight heparin (LMWH) was evaluated on Bleeding profile (overall bleeding, intracranial hemorrhage). Apixaban and rivaroxaban offered a safer bleeding profile, including lower risks of overall bleeding and intracranial hemorrhage, compared to LMWH in patients with cancer-associated VTE.
Synapse has enriched 10 related papers. Consider them for comparative context: